407 related articles for article (PubMed ID: 33150145)
1. Gut Microbiota, Peroxisome Proliferator-Activated Receptors, and Hepatocellular Carcinoma.
Yu Q; Wu L; Ji J; Feng J; Dai W; Li J; Wu J; Guo C
J Hepatocell Carcinoma; 2020; 7():271-288. PubMed ID: 33150145
[TBL] [Abstract][Full Text] [Related]
2. Crosstalk between PPARs and gut microbiota in NAFLD.
Wu L; Li J; Feng J; Ji J; Yu Q; Li Y; Zheng Y; Dai W; Wu J; Guo C
Biomed Pharmacother; 2021 Apr; 136():111255. PubMed ID: 33485064
[TBL] [Abstract][Full Text] [Related]
3. Berberine activates PPARĪ“ and promotes gut microbiota-derived butyric acid to suppress hepatocellular carcinoma.
Shou JW; Shaw PC
Phytomedicine; 2023 Jul; 115():154842. PubMed ID: 37148713
[TBL] [Abstract][Full Text] [Related]
4. Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease.
Ponziani FR; Bhoori S; Castelli C; Putignani L; Rivoltini L; Del Chierico F; Sanguinetti M; Morelli D; Paroni Sterbini F; Petito V; Reddel S; Calvani R; Camisaschi C; Picca A; Tuccitto A; Gasbarrini A; Pompili M; Mazzaferro V
Hepatology; 2019 Jan; 69(1):107-120. PubMed ID: 29665135
[TBL] [Abstract][Full Text] [Related]
5. Roles of peroxisome proliferator-activated receptors in hepatocellular carcinoma.
Zhao Y; Tan H; Zhang X; Zhu J
J Cell Mol Med; 2023 Nov; 28(5):e18042. PubMed ID: 37987033
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome Proliferator-Activated Receptors and Their Agonists in Nonalcoholic Fatty Liver Disease.
Choudhary NS; Kumar N; Duseja A
J Clin Exp Hepatol; 2019; 9(6):731-739. PubMed ID: 31889755
[TBL] [Abstract][Full Text] [Related]
7. Gut microbiota, fatty liver disease, and hepatocellular carcinoma.
Chu H; Williams B; Schnabl B
Liver Res; 2018 Mar; 2(1):43-51. PubMed ID: 30416839
[TBL] [Abstract][Full Text] [Related]
8. New insights and therapeutic implication of gut microbiota in non-alcoholic fatty liver disease and its associated liver cancer.
Ezzaidi N; Zhang X; Coker OO; Yu J
Cancer Lett; 2019 Sep; 459():186-191. PubMed ID: 31185249
[TBL] [Abstract][Full Text] [Related]
9. The role of gut microbiota in liver disease development and treatment.
Wang L; Wan YY
Liver Res; 2019 Mar; 3(1):3-18. PubMed ID: 32461811
[TBL] [Abstract][Full Text] [Related]
10. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
Suk KT; Kim DJ
Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
[TBL] [Abstract][Full Text] [Related]
11. Gut microbiota abnormalities, small intestinal bacterial overgrowth, and non-alcoholic fatty liver disease: An emerging paradigm.
Ghoshal UC; Goel A; Quigley EMM
Indian J Gastroenterol; 2020 Feb; 39(1):9-21. PubMed ID: 32291578
[TBL] [Abstract][Full Text] [Related]
12. Gut Microbiota and Hepatocellular Carcinoma.
Tao X; Wang N; Qin W
Gastrointest Tumors; 2015 May; 2(1):33-40. PubMed ID: 26673641
[TBL] [Abstract][Full Text] [Related]
13. Interactions between Host PPARs and Gut Microbiota in Health and Disease.
Hasan AU; Rahman A; Kobori H
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658440
[TBL] [Abstract][Full Text] [Related]
14. Gut microbial dysbiosis associates hepatocellular carcinoma via the gut-liver axis.
Jiang JW; Chen XH; Ren Z; Zheng SS
Hepatobiliary Pancreat Dis Int; 2019 Feb; 18(1):19-27. PubMed ID: 30527903
[TBL] [Abstract][Full Text] [Related]
15. Abnormal Metabolism in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Mechanistic Insights to Chemoprevention.
Orabi D; Berger NA; Brown JM
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298687
[TBL] [Abstract][Full Text] [Related]
16. Nuclear receptors and nonalcoholic fatty liver disease.
Cave MC; Clair HB; Hardesty JE; Falkner KC; Feng W; Clark BJ; Sidey J; Shi H; Aqel BA; McClain CJ; Prough RA
Biochim Biophys Acta; 2016 Sep; 1859(9):1083-1099. PubMed ID: 26962021
[TBL] [Abstract][Full Text] [Related]
17. PPAR Could Contribute to the Pathogenesis of Hepatocellular Carcinoma.
Kimura O; Kondo Y; Shimosegawa T
PPAR Res; 2012; 2012():574180. PubMed ID: 23316217
[TBL] [Abstract][Full Text] [Related]
18. Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature.
Milosevic I; Vujovic A; Barac A; Djelic M; Korac M; Radovanovic Spurnic A; Gmizic I; Stevanovic O; Djordjevic V; Lekic N; Russo E; Amedei A
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658519
[TBL] [Abstract][Full Text] [Related]
19. Antioxidant and anti-inflammatory agents in chronic liver diseases: Molecular mechanisms and therapy.
Zhang CY; Liu S; Yang M
World J Hepatol; 2023 Feb; 15(2):180-200. PubMed ID: 36926234
[TBL] [Abstract][Full Text] [Related]
20. Gut microbiota contribution to hepatocellular carcinoma manifestation in non-alcoholic steatohepatitis.
Liakina V; Strainiene S; Stundiene I; Maksimaityte V; Kazenaite E
World J Hepatol; 2022 Jul; 14(7):1277-1290. PubMed ID: 36158907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
